The ETF is a well-conceived but currently expensive way to own what are considered late-stage biotechnologies. The probability-weighted base fair NAV is $37.86,...
Market Samachar is a news aggregator. This article was originally published by seekingalpha.com. Tap the button above to read the full story on their site.